BLAINJECTIONINJECTABLEPriority Review
Approved
May 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
7/8 — Comprehensive
Priority Review
ENTYVIO (vedolizumab) by Takeda is integrin receptor antagonists [moa]. Approved for integrin receptor antagonist [epc]. First approved in 2014.
Drug data last refreshed 18h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENTYVIO (vedolizumab) is a monoclonal antibody integrin receptor antagonist approved in 2014 for inflammatory bowel disease. It selectively blocks α4β7 integrin on gut-homing lymphocytes, reducing intestinal inflammation. The drug is administered via intravenous injection and represents a targeted approach to IBD treatment.
$0.1BPart D
PeakStable
ENTYVIO is at peak maturity with ~$100M in annual Part D spending and 11,695 claims, indicating a stable commercial franchise with established demand but limited growth upside.
Mechanism of Action
Integrin Receptor Antagonists
Pharmacologic Class:
Integrin Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Started Oct 2025
70 enrolled
Ulcerative ColitisCrohn's Disease
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
Started Oct 2025
120 enrolled
Inflammatory Bowel Disease (IBD)Crohn&Amp;#39;s Disease (CD)Ulcerative Colitis (UC)
CurQD as Add-On Therapy in Vedolizumab-Treated Ulcerative Colitis Patients: Retrospective Cohort Study
Started Sep 2025
400 enrolled
Ulcerative Colitis (UC)
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Started Jul 2025
80 enrolled
Immune Checkpoint Inhibitor-Related Colitis
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Started Jun 2025
573 enrolled
Ulcerative Colitis
Worked on ENTYVIO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.